Abstract
Several lines of evidence have extensively demonstrated that peroxynitrite plays a pivotal role in Central Nervous System (CNS) injuries. The present study was aimed at elucidating the molecular mechanism by which propofol attenuates peroxynitrite-mediated injury in the brain. Primary cultured astroglial cells were incubated for 18 h with a known peroxynitrite donor (SIN-1,3 μM) in the presence or absence of propofol (40 μM, 80 mM and 160 μM). The protective effects of propofol were evaluated by MTT cytotoxicity assay, LDH release, and caspase-3 activation by Western blot analysis. Appropriate propofol concentrations (ranging from 40 μM to 160 μM) significantly increased HO- 1 expression and attenuated SIN-1-mediated cytotoxicity and caspase-3 activation. The protective effects of propofol were mitigated by the addition of tin-mesoporphirin (SnMP), a potent inhibitor of HO activity. The addition of a specific synthetic inhibitor of NF-κB abolished propofol-mediated HO-1 induction, suggesting a possible role for this nuclear transcriptional factor in our experimental conditions. These findings indicate that propofol attenuates peroxynitritemediated apoptosis in astroglial cells, a property that may be relevant in both physiological and pathological processes in the CNS.
Keywords: heme oxygenase, peroxynitrite, astrocytes, apoptosis, propofol, caspase-3
Current Neurovascular Research
Title: Propofol Inhibits Caspase-3 in Astroglial Cells: Role of Heme Oxygenase-1
Volume: 2 Issue: 2
Author(s): Rosaria Acquaviva, Agata Campisi, Giuseppina Raciti, Roberto Avola, Maria Luisa Barcellona, Luca Vanella and Giovanni Li Volti
Affiliation:
Keywords: heme oxygenase, peroxynitrite, astrocytes, apoptosis, propofol, caspase-3
Abstract: Several lines of evidence have extensively demonstrated that peroxynitrite plays a pivotal role in Central Nervous System (CNS) injuries. The present study was aimed at elucidating the molecular mechanism by which propofol attenuates peroxynitrite-mediated injury in the brain. Primary cultured astroglial cells were incubated for 18 h with a known peroxynitrite donor (SIN-1,3 μM) in the presence or absence of propofol (40 μM, 80 mM and 160 μM). The protective effects of propofol were evaluated by MTT cytotoxicity assay, LDH release, and caspase-3 activation by Western blot analysis. Appropriate propofol concentrations (ranging from 40 μM to 160 μM) significantly increased HO- 1 expression and attenuated SIN-1-mediated cytotoxicity and caspase-3 activation. The protective effects of propofol were mitigated by the addition of tin-mesoporphirin (SnMP), a potent inhibitor of HO activity. The addition of a specific synthetic inhibitor of NF-κB abolished propofol-mediated HO-1 induction, suggesting a possible role for this nuclear transcriptional factor in our experimental conditions. These findings indicate that propofol attenuates peroxynitritemediated apoptosis in astroglial cells, a property that may be relevant in both physiological and pathological processes in the CNS.
Export Options
About this article
Cite this article as:
Acquaviva Rosaria, Campisi Agata, Raciti Giuseppina, Avola Roberto, Barcellona Luisa Maria, Vanella Luca and Volti Li Giovanni, Propofol Inhibits Caspase-3 in Astroglial Cells: Role of Heme Oxygenase-1, Current Neurovascular Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567202053586820
DOI https://dx.doi.org/10.2174/1567202053586820 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Image-Based Stem-Cell Labeling and Tracking, and Scaffold-Based Organ Development in Cardiovascular Disease
Recent Patents on Medical Imaging Gastric Mucosal Protection And Central Nervous System
Current Pharmaceutical Design Flavonols and Flavones – Protecting Against Myocardial Ischemia/ Reperfusion Injury by Targeting Protein Kinases
Current Medicinal Chemistry Δ<sup>α,β</sup>-Butenolides [Furan-2(5<i>H</i>)-ones]: Ring Construction Approaches and Biological Aspects - A Mini-Review
Mini-Reviews in Organic Chemistry Biological Activities of Yarrow Species (Achillea spp.)
Current Pharmaceutical Design Nonnucleoside Inhibitors of Adenosine Kinase
Current Pharmaceutical Design Potential of Resveratrol in Preventing the Development of Heart Failure
Current Chemical Biology Mitochondria: the Headquarters in Ischemia-Induced Neuronal Death
Central Nervous System Agents in Medicinal Chemistry Emerging Anti-inflammatory Therapies for Atherosclerosis
Current Pharmaceutical Design The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice
CNS & Neurological Disorders - Drug Targets Xanthine Derivatives in the Heart: Blessed or Cursed?
Current Medicinal Chemistry Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design NGS of microRNAs Involved in Cardioprotection Induced by Sevoflurane Compared to Propofol in Myocardial Revascularization Surgery: The ACDHUVV-16 Clinical Trial
Current Medicinal Chemistry MicroRNA-16-5p Aggravates Myocardial Infarction Injury by Targeting the Expression of Insulin Receptor Substrates 1 and Mediating Myocardial Apoptosis and Angiogenesis
Current Neurovascular Research Role of Nitric Oxide in the Modulation of Angiogenesis
Current Pharmaceutical Design Expression and Function of the Leukocyte Integrins in Organ Transplant Rejection
Current Medicinal Chemistry Evaluation of Eudragit® Retard Polymers for the Microencapsulation of Alpha-Lipoic Acid
Current Drug Delivery Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Current Diabetes Reviews Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry